Published in Cancer Weekly, November 27th, 2001
ASTA Medica Oncology develops, produces, and markets oncology products worldwide. ASTA Medica Oncology's pro forma sales, primarily of chemotherapy agents, totaled approximately US$130 million in 2000. The company's leading products include cyclophosphamide (marketed as Endoxan), ifosfamide (marketed as Holoxan and as Ifex in the United States), and mesna (marketed as Uromitexan and as Mesnex in the United States).
"We believe our combined strengths...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.